Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide

U.S. Brand Name

Genvoya

Abbreviation(s)

EVG/COBI/FTC/TAF

First U.S. Approval

November 5, 2015

Component ARVs

Tenofovir Alafenamide

NRTI Based?

No

One Dose Daily?

Yes

Single Tablet Regimen

Yes

U.S. FDA Label

U.S. Manufacturer

Gilead Sciences

Other Reference Links

National HIV Curriculum

Clinical Info Drug Database

Formulations

Strength	Formulation	Image	Description	Boosted
EVG 150 mg, COBI 150 mg, FTC 200 mg, TAF 10 mg	Film-Coated Tablets	X	The tablets are green, capsule-shaped, film-coated tablets, debossed with "GSI" on one side of the tablet and the number "510" on the other side of the tablet.	Yes

Adult dosing

Dosage	Formulation
1 tablet daily	Tablet

Pediatric dosing

References

Assistance Programs

Gilead Advancing Access

Displaying 1 - 10 of 10

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Darunavir EVG/c 993	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for decreased or increased elvitegravir, cobicistat, and / or darunavir effects	Cmin decreased 21%	150 / 150 mg once daily	Elvitegravir AUC decrease 20%, Cmin decrease 52%; Cobicistat AUC decrease 15-20%	Use alternative agents. One study supports clinical use of elvitegravir / cobicistat with darunavir 800 mg daily in treatment experienced patients.
Atazanavir EVG/c 840	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir Cmax decreased 24%, Cmin decreased 20%	Elvitegravir 85 mg daily with cobicistat 150 mg daily	Elvitegravir AUC increased 17%, Cmax decreased 16%, Cmin increased 83%	Use alternative agents
Nevirapine Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide 607	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir / cobicistat	Potentially decreased or increased elvitegravir, cobicistat and / or nevirapine effects	Not studied		Not studied	Use alternative agents
Etravirine Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide 559	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potentially decreased or increased elvitegravir, cobicistat and / or etravirine effects	No significant change	Elvitegravir 150 mg daily	No significant change	Avoid combination and use alternative agents
Efavirenz Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide 442	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir / cobicistat	Potentially decreased or increased elvitegravir, cobicistat and / or efavirenz effects	Not studied (may decrease elvitegravir and cobicistat levels)		Not studied	Use alternative agents
Maraviroc Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide 43	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects				Reduce dose of maraviroc to 150 mg BID
Elvitegravir
Cobicistat
Tenofovir alafenamide (TAF)
Emtricitabine

Subscribe to Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide